Bank Of Montreal Affimed N.V. Transaction History

Bank Of Montreal

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 08, 2024	SELL	$0.32 - $0.62 $320 - $620	-1,000 Reduced 6.83%	13,650 $8,000
Q3 2023 Nov 01, 2023	SELL	$0.46 - $0.65 $1,265 - $1,787	-2,750 Reduced 15.8%	14,650 $7,000
Q2 2023 Aug 02, 2023	BUY	$0.57 - $1.08 $9,918 - $18,792	17,400 New	17,400 $10,000
Q1 2023 Jun 13, 2024	BUY	$0.66 - $1.29 $9,262 - $18,103	14,034 New	14,034 $10,000
Q4 2021 Feb 11, 2022	SELL	$5.37 - $7.07 $66,652 - $87,752	-12,412 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$5.54 - $7.51 $68,762 - $93,214	12,412 New	12,412 $76,000

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $185M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Bank Of Montreal , based on Form 13F filings with the SEC.

Stay updated on Bank Of Montreal with notifications on news.